New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Core Insights - Bright Minds Biosciences Inc. (NASDAQ:DRUG) stock is experiencing a significant increase following the positive topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) [1][2]. Efficacy Results - The study met its primary efficacy endpoints in both cohorts, showing a robust reduction in seizures with a favorable safety profile [2]. - Absence Seizure Cohort (n=11) demonstrated a 73.1% median reduction in the number of absence seizures lasting ≥3 seconds (p = 0.012) and a 74.4% median reduction in total seizure time during 24 hours (p = 0.012) [3]. - DEE Cohort (n=6) showed a 63.3% median reduction in major motor seizures, with a 60.3% reduction in LGS patients and a 76.1% reduction in other DEE patients [4]. Safety Profile - BMB-101 was generally well tolerated, with 79.6% of treatment-emergent adverse events classified as mild and 17.2% as moderate, and no serious treatment-related adverse events reported [4]. Additional Effects - The study also noted a 90% increase in REM sleep duration (from 56.2 minutes at baseline to 106.7 minutes on BMB-101), while overall sleep duration remained stable [5]. Future Plans - Bright Minds Biosciences is preparing for global registrational trials in Absence Seizures and DEE, with additional data on long-term outcomes expected throughout the year [6]. - The company plans to initiate a study in Prader-Willi Syndrome, anticipated to start in Q1 2026 [6]. Stock Performance - Following the announcement, Bright Minds Biosciences stock rose by 22.23%, reaching $97.80 [6].